Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTLA-2002 in Hereditary Angioedema (HAELO)
NCT06634420Phase 3Active, not recruiting
- Sponsor
- Intellia Therapeutics
- Start
- Jan 2025
- Primary completion
- Feb 2026
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in hereditary angioedema (HAE) comparing Arm A: NTLA-2002 with Arm B: Placebo (2 arms). Primary endpoint: Time-normalized number of Investigator-confirmed HAE attacks. Started Jan 2025; status: active, not recruiting.
02
Drugs
lonvoguran
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT06634420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06634420.